Company Overview and News

37
CYH / Community Health Systems, Inc. FORM 8-K (Current Report)

2018-07-07 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
CYH

61
American Airlines, MiMedx Tumble into Tuesday’s 52-Week Low Club

2018-07-03 247wallst
July 3, 2018: Here are four stocks trading with heavy volume among 43 equities making new 52-week lows in Tuesday’s shortened session. On the NYSE advancers led decliners by about 1.69 to 1 and on the Nasdaq, advancers led decliners by about 1.2 to 1.
CYH MDXG CUKPF AAL CCL CCL CYHHZ CUK

31
Community Health, Frontier Communications Dive Friday’s 52-Week Low Club

2018-06-29 247wallst
June 29, 2018: Here are four stocks trading with heavy volume among 96 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.4 to 1 and on the Nasdaq, advancers led decliners by about 1.19 to 1.
CYH BRFS LBTYK FTRPR LILAB LBTY LILAK LBTYB LBTYA CYHHZ FTR LILA

14
CYH / Community Health Systems, Inc. 8-K (Current Report)

2018-06-28 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
CYH

64
Community Health Arm to Divest AllianceHealth Deaconess

2018-06-27 zacks
Community Health Systems, Inc. (CYH - Free Report) recently announced that one of its units has signed a definitive agreement to sell 291-bed AllianceHealth Deaconess hospital in Oklahoma City, OK along with other related businesses to a subsidiary of INTEGRIS Health. The transaction is expected to close in the third quarter of 2018, subject to customary regulatory approvals and closing conditions.
CYH RNVAZ RNVA WCG CYHHZ ANTM HUM RNVAW

14
CYH / Community Health Systems, Inc. FORM 8-K (Current Report)

2018-06-25 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
CYH

63
Community Health's Ratings Downgraded by Moody's

2018-06-21 zacks
Credit rating giant Moody’s Investors Service recently downgraded the ratings of Community Health Systems (CYH - Free Report) . The ratings include Corporate Family Rating (CFR), which were lowered to Caa2 from Caa1 and the Probability of Default Rating (PDR), which deteriorated to Caa2-PD/LD from Caa1-PD. The ratings outlook remains stable. The above was based on the company’s announcement of the final results of its debt exchange wherein holders exchanged part of unsecured notes due 2019, 2020 and 2022 for new junior lien notes due 2023 and 2024.
CYH MS.PRE WCG MS.PRF MS.PRG ANTM HUM MS.PRA MS.PRI MS.PRK CYHHZ MS

12
CYH / Community Health Systems, Inc. FORM 8-K (Current Report)

2018-06-20 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
CYH

26
RENNOVA HEALTH REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

2018-06-19 globenewswire
WEST PALM BEACH, Fla, June 19, 2018 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTCQB: RNVA), (OTCQB: RNVAW), (“Rennova” or the “Company”) a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that acquired its second rural hospital in Tennessee on June 1, 2018, reports financial results for the three months ended March 31, 2018 and provides a business update.
CYH RNVAZ RNVA CYHHZ RNVAW

103
Earnings or Revenue-Weighted ETFs: Who Won in Q1?

2018-06-12 zacks
We are at the end of the Q1 earnings season. As of now, 98.6% of the S&P 500 companies have reported earnings for Q1, with a 24.3% year-over-year jump on 8.7% revenue growth. Almost 76.9% of the companies beat on earnings while 74.4% beat on revenues, per the Earnings Trends issued on May 31.
PBF KEM CYH MTCH XOM PENN MSFT CYHHZ TECD UTX INT

12
Community Health Systems Debt Exchange Offer Creates Opportunity For Near Term Retail Investors

2018-06-11 seekingalpha
Community Health Systems recently offered to exchange its 2019, 2020, and 2022 notes with 2023 and 2024 notes, respectively.
CYH CYHHZ

18
Natus Medical Comments on ISS Report

2018-06-11 globenewswire
Board Urges Shareholders to Vote on the WHITE Proxy Card FOR the Election of Doris Engibous and Robert Weiss
COO CYH CYHHZ BABY

13
CYH / Community Health Systems, Inc. FORM 8-K (Current Report)

2018-06-11 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
CYH

10
CYH / Community Health Systems, Inc. FORM 8-K (Current Report)

2018-06-06 sec.gov
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
CYH

304
Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors.
NKTR DCPH VXRT LOXO NWBO PODD MRSN SHPG BPMC MYL IMMU IDRA IOVA CTMX KITE CYHHZ BMY CYH AMAG GILD NWBOW PTN PDM K JNCE MRK GHDX ALNY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CYH / Community Health Systems, Inc. on message board site Silicon Investor.

CYH.Ase
CUSIP: 203668108